Granules India Ltd (GRANULES) Q4FY25 Concall Summary - Mar-2025 Qtr
Performance Overview
- Granules India reported Q4 FY25 revenue of Rs. 11,974 million, a 2% increase YoY and a 5% increase QoQ.
- Full-year revenue for FY25 was Rs. 44,816 million, slightly lower than FY24's Rs. 45,064 million.
- Formulation sales grew by 18% YoY despite a voluntary production pause at the Gagillapur facility in September 2024 due to US FDA observations.
- The company received a warning letter from the US FDA for its Gagillapur facility in February 2025. Remediation efforts are ongoing.
- Granules India entered the peptide therapeutics market with the acquisition of Senn Chemicals.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.